371 related articles for article (PubMed ID: 34163421)
21. [Future perspectives of immunotherapy against ALS].
Urushitani M
Rinsho Shinkeigaku; 2009 Nov; 49(11):818-20. PubMed ID: 20030219
[TBL] [Abstract][Full Text] [Related]
22. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.
Southwell AL; Franciosi S; Villanueva EB; Xie Y; Winter LA; Veeraraghavan J; Jonason A; Felczak B; Zhang W; Kovalik V; Waltl S; Hall G; Pouladi MA; Smith ES; Bowers WJ; Zauderer M; Hayden MR
Neurobiol Dis; 2015 Apr; 76():46-56. PubMed ID: 25662335
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
24. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.
Carrozza F; Santoni M; Piva F; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R; Battelli N; Tamberi S
Crit Rev Oncol Hematol; 2018 Nov; 131():1-6. PubMed ID: 30293699
[TBL] [Abstract][Full Text] [Related]
25. Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.
Sheikhi A; Jafarzadeh A; Kokhaei P; Hojjat-Farsangi M
Iran J Immunol; 2016 Sep; 13(3):148-66. PubMed ID: 27671507
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
27. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease.
Kayed R
Hum Vaccin; 2010 Nov; 6(11):931-5. PubMed ID: 20980799
[TBL] [Abstract][Full Text] [Related]
28. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases.
González H; Pacheco R
J Neuroinflammation; 2014 Dec; 11():201. PubMed ID: 25441979
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
30. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.
Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G
J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910
[TBL] [Abstract][Full Text] [Related]
31. Antigen Targets for the Development of Immunotherapies in Leukemia.
Bauer J; Nelde A; Bilich T; Walz JS
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897713
[TBL] [Abstract][Full Text] [Related]
32. Anti-Inflammatory Activities of Marine Algae in Neurodegenerative Diseases.
Barbalace MC; Malaguti M; Giusti L; Lucacchini A; Hrelia S; Angeloni C
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234555
[TBL] [Abstract][Full Text] [Related]
33. Targeting
Péchiné S; Bruxelle JF; Janoir C; Collignon A
Front Microbiol; 2018; 9():1009. PubMed ID: 29875742
[TBL] [Abstract][Full Text] [Related]
34. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
35. Emerging applications of anticytokine vaccines.
Delavallée L; Assier E; Semerano L; Bessis N; Boissier MC
Expert Rev Vaccines; 2008 Dec; 7(10):1507-17. PubMed ID: 19053207
[TBL] [Abstract][Full Text] [Related]
36. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Wirth TC; Kühnel F
Front Immunol; 2017; 8():1848. PubMed ID: 29312332
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy as treatment for Alzheimer's disease.
Hawkes CA; McLaurin J
Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
[TBL] [Abstract][Full Text] [Related]
38. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
39. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies.
Wirth TC
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):101-10. PubMed ID: 24410473
[TBL] [Abstract][Full Text] [Related]
40. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
